Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lovastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ITGB2 | P05107 | 2/20 | 1.00 |
| ▸ | ICAM1 | P05362 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 2/20 | 1.00 |
| ▸ | ITGAL | P20701 | 2/20 | 1.00 |
| ▸ | TACR2 | P21452 | 2/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lovastatin SCHEMBL5063297 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A | |
| Lovastatin SCHEMBL16750775 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A | |
| Lovastatin SCHEMBL13865314 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A | |
| Lovastatin SCHEMBL21340570 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A | |
| Lovastatin SCHEMBL23468171 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A | |
| Lovastatin SCHEMBL8291088 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A | |
| Lovastatin SCHEMBL23636214 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A | |
| Lovastatin SCHEMBL21340553 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A | |
| Lovastatin SCHEMBL21340572 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A | |
| Lovastatin SCHEMBL2894668 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190277833-A1 | ANTI-METHANOGENIC COMPOSITIONS | SYNTHETIC BIOLOGICS INC (US) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190277833-A1 | ANTI-METHANOGENIC COMPOSITIONS | ME3, HSD17B10, OAT | HMGCR 201/4885CYP3A4 419/4885LMNA 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.